Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats

Journal of Clinical Investigation

Volumn 98, Issue 10, 1996, Pages 2364-2372

  Niranjan, Viswanathan ^b   Télémaque, Sabine ^a   De Wit, Damiane ^a   Gerard, Robert D ^b   Yanagisawa, Masashi ^a,c  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

adenovirus mediated gene transfer; blood pressure; endothelin antagonist; endothelin converting enzyme; liver

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; COMPLEMENTARY DNA; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PREPROENDOTHELIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; VIRUS RECOMBINANT;

EID: 0029826983     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119049     Document Type: Article

References (64)

1. Rubanyi, G.M., and M.A. Polokoff. 1994. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46:325-415.
2. Simonson, M.S., and M.J. Dunn. 1993. Endothelin peptides and the kidney. Annu. Rev. Physiol. 55:249-265.
3. Xu, D., N. Emoto, A. Giaid, C. Slaughter, S. Kaw, D. deWit, and M. Yanagisawa. 1994. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 78:473-485.
4. Aral, H., S. Hori, I. Aramori, H. Ohkubo, and S. Nakanishi. 1990. Cloning and expression of a cDNA encoding an endothelin receptor. Nature (Lond.). 348:730-732.
5. Sakurai, T., M. Yanagisawa, Y. Takuwa, H. Miyazaki, S. Kimura, K. Goto, and T. Masaki. 1990. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (Lond.). 348:732-735.
6. Schiffrin, E.L., and G. Thibault. 1991. Plasma endothelin in human essential hypertension. Am. J. Hypertens. 4:303-308.
7. Saito, Y., K. Nakao, M. Mukoyama, and H. Imura. 1990. Increased plasma endothelin level in patients with essential hypertension. N. Engl. J. Med. 322:205.
8. Shichiri, M., Y. Hirata, K. Ando, T. Emori, K. Ohta, S. Kimoto, M. Ogura, A. Inoue, and F. Marumo. 1990. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension (Dallas). 15:493-496.
9. Widimsky, J., Jr., K. Horky, and J. Dvorakova. 1991. Plasma endothelin-1,2 levels in mild and severe hypertension. J. Hypertens. 9(Suppl.):S194-S195.
10. Yokokawa, K., H. Tahara, M. Kohno, K. Murakawa, K. Yasunari, K. Nakagawa, T. Hamada, S. Otani, M. Yanagisawa, and T. Takeda. 1991. Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann. Intern. Med. 114:213-215.
11. Suzuki, N., T. Miyauchi, Y. Tomobe, H. Matsumoto, K. Goto, T. Masaki, and M. Fujino. 1990. Plasma concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt hypertensive rats. Biochem. Biophys. Res. Commun. 167:941-947.
12. Kohno, M., K. Murakawa, T. Horio, K. Yokokawa, K. Yasunari, T. Fukui, and T. Takeda. 1991. Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension (Dallas). 18:93-100.
13. Haynes, W.G., and D.J. Webb. 1994. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet (N. Am. Ed.). 24:832-833.
14. Haynes, W.G., C.J. Ferro, K.P. O'Kane, D. Somerville, C.C. Lomax, and D.J. Webb. 1996. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 93:1860-1870.
15. Ohlstein, E.H., P. Nambi, S.A. Douglas, K.M. Edwards, M. Gellai, A. Lago, J.D. Leber, R.D. Cousins, A. Gao, J.S. Frazee, et al. 1994. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc. Natl. Acad. Sci. USA. 91:8052-8056.
16. Gardiner, S.M., J.E. March, P.A. Kemp, J.J. Mullins, and T. Bennett. 1995. Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Br. J. Pharmacol. 116:2237-2244.
17. Stein, P.D., J.T. Hunt, D.M. Floyd, S. Moreland, K.E. Dickinson, C. Mitchell, E.C.-K. Liu, M.L. Webb, N. Murugesan, J. Dickey, et al. 1994. The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide. J. Med. Chem. 37:329-331.
18. Thompson, A., C.R. Valeri, and W. Lieberthal. 1995. Endothelin receptor A blockade alters hemodynamic response to nitric oxide inhibition in rats. Am. J. Physiol. 269:H743-H748.
19. McMahon, E.G., M.A. Palomo, and W.M. Moore. 1991. Phosphoramidon blocks the presser activity of big endothelin[1-39] and lowers blood pressure in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 17(Suppl. 7):S29-S33.
20. De Lombaert, S., R.D. Ghai, A.Y. Jeng, A.J. Trapani, and R.L. Webb. 1994. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. Biochem. Biophys. Res. Commun. 204:407-412.
21. Deng, A.Y., H. Dene, M. Pravenec, and J.P. Rapp. 1994. Genetic mapping of two new blood pressure quantitative trait loci in the rat by genotyping endothelin system genes. J. Clin. Invest. 93:2701-2709.
22. Kurihara, Y., H. Kurihara, H. Suzuki, T. Kodama, K. Maemura, R. Nagai, H. Oda, T. Kuwaki, W.-H. Cao, N. Kamada, et al. 1994. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature (Lond.). 368:703-710.
23. Yanagisawa, M., H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, and T. Masaki. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (Lond.). 332:411-415.
24. Yasujima, M., K. Abe, M. Kanazawa, K. Yoshida, M. Sato, K. Takeuchi, K. Tsunoda, K. Kudo, M. Kohzuki, K. Omata, and K. Yoshinaga. 1990. Chronic effects of synthetic endothelin on blood pressure and sodium excretion in rats. Am. J. Hypertens. 3:635-637.
25. Wilkins, F.C., Jr., A. Alberola, H.L. Mizelle, T.J. Opgenorth, and J.P. Granger. 1995. Systemic hemodynamics and renal function during long-lerm pathophysiological increases in circulating endothelin. Am. J. Physiol. 268:R375-R381.
26. Lerman, A., F.L. Hildebrand, Jr., L.L. Aarhus, and J.C. Burnett, Jr. 1991. Endothelin has biological actions at pathophysiological concentrations. Circulation. 83:1808-1814.
27. Herz, J., and R.D. Gerard. 1993. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. USA. 90:2812-2816.
28. Itoh, Y., M. Yanagisawa, S. Ohkubo, C. Kimura, T. Kosaka, A. Inoue, N. Ishida, Y. Mitsui, H. Onda, M. Fujino, and T. Masaki. 1988. Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin. FEBS Lett. 231:440-444.
29. Suzuki, N., H. Matsumoto, T. Miyauchi, C. Kitada, M. Tsuda, K. Goto, T. Masaki, and M. Fujino. 1991. Sandwich-enzyme immunoassays for endothelin family peptides. J. Cardiovasc. Pharmacol. 17(Suppl. 7):S420-S422.
30. Watanabe, T., N. Suzuki, N. Shimamoto, M. Fujino, and A. Imada. 1991. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ. Res. 69:370-377.
31. Bajocchi, G., S.H. Feldman, R.G. Crystal, and A. Mastrangeli. 1993. Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nat. Genet. 3:229-234.
32. Zar, J.H. 1984. Biostatistical Analyses. Prentice-Hall, Englewood Cliffs, NJ. pp. 176-179.
33. Ostle, B. 1963. Statistics in Research. Iowa State University Press, Ames, IA. pp. 56-58.
34. Sogabe, K., H. Nirei, M. Shoubo, A. Nomoto, S. Ao, Y. Notsu, and T. Ono. 1993. Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J. Pharmacol. Exp. Ther. 264:1040-1046.
35. Ishikawa, K., M. Ihara, K. Noguchi, T. Mase, N. Mino, T. Saeki, T. Fukuroda, T. Fukami, S. Ozaki, T. Nagase, et al. 1994. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc. Natl. Acad. Sci. USA. 91:4892-4896.
36. Kochanek, S., P.R. Clemens, K. Mitani, H.H. Chen, S. Chan, and C.T. Caskey. 1996. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc. Natl. Acad. Sci. USA. 93:5731-5736.
37. Hemsen, A., G. Ahlborg, A. Ottosson-Seeberger, and J.M. Lundberg. 1995. Metabolism of big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21). Regul. Pept. 55:287-297.
38. Corder, R., and J.R. Vane. 1995. Radioimmunoassay evidence that the pressor effect of big endothelin-1 is due to local conversion to endothelin-1. Biochem. Pharmacol. 49:375-380.
39. Oishi, R., H. Nonoguchi, K. Tomita, and F. Marumo. 1991. Endothelin-1 inhibits AVP-stimulated osmotic water permeability in rat inner medullary collecting duct. Am. J. Physiol. 261:F951-F956.
40. Tomita, K., H. Nonoguchi, and F. Marumo. 1990. Effects of endothelin on peptide-dependent cyclic adenosine monophosphate accumulation along the nephron segments of the rat. J. Clin. Invest. 85:2014-2018.
41. Gratton, J.P., M.C. Maurice, G.A. Rae, and P. D'Orleans-Juste. 1995. Pharmacological properties of endothelins and big endothelins in ketamine/xylazine or urethane anesthetized rats. Am. J. Hypertens. 8:1121-1127.
42. Ohno, A., M. Naruse, S. Kato, M. Hosaka, K. Naruse, H. Demura, and N. Sugino. 1992. Endothelin-specific antibodies decrease blood pressure and increase glomerular filtration rate and renal plasma flow in spontaneously hypertensive rats. J. Hypertens. 10:781-785.
43. Nishikibe, M., S. Tsuchida, M. Okada, T. Fukuroda, K. Shimamoto, M. Yano, K. Ishikawa, and F. Ikemoto. 1993. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 52:717-724.
44. Douglas, S.A., M. Gellai, M. Ezekiel, and E.H. Ohlstein. 1994. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J. Hypertens. 12:561-567.
45. Ohlstein, E.H., S.A. Douglas, M. Ezekiel, and M. Gellai. 1993. Antihypertensive effects of the endothelin receptor antagonist BQ-123 in conscious spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 22(Suppl. 8):S321-S324.
46. Schiffrin, E.L., R. Lariviere, J.S. Li, and P. Sventek. 1996. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J. Vasc. Res. 33:235-248.
47. Lerman, A., B.S. Edwards, J.W. Hallett, D.M. Heublein, S.M. Sandberg, and J.C. Burnett, Jr. 1991. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med. 325:997-1001.
48. Sudo, N., K. Kamoi, M. Ishibashi, and T. Yamaji. 1993. Plasma endothelin-1 and big endothelin-1 levels in women with pre-eclampsia. Acta Endocrinol. 129:114-120.
49. Kamoi, K., N. Sudo, M. Ishibashi, and T. Yamaji. 1990. Plasma endothelin-1 levels in patients with pregnancy-induced hypertension. N. Engl. J. Med. 323:1486-1487.
50. Stewart, D.J., G. Kubac, K.B. Costello, and P. Cernacek. 1991. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J. Am. Coll. Cardiol. 18:38-43.
51. Druml, W., H. Steltzer, W. Waldhausl, K. Lenz, A. Hammerle, H. Vierhapper, S. Gasic, and O.F. Wagner. 1993. Endothelin-1 in adult respiratory distress syndrome. Am. Rev. Resp. Dis. 148:1169-1173.
52. Shennib, H., C. Serrick, D. Saleh, A. Reis, D.J. Stewart, and A. Giaid. 1995. Plasma endothelin-1 levels in human lung transplant recipients. J. Cardiovasc. Pharmacol. 26(Suppl. 3):S516-S518.
53. Koller, J., P. Mair, C. Wieser, A. Pomaroli, B. Puschendorf, and M. Herold. 1991. Endothelin and big endothelin concentrations in injured patients. N. Engl. J. Med. 325:1518.
54. Ishibashi, M., K. Saito, K. Watanabe, S. Uesugi, H. Furue, and T. Yamaji. 1991. Plasma endothelin-1 levels in patients with disseminated intravascular coagulation. N. Engl. J. Med. 324:1516-1517.
55. Tomita, K., K. Ujiie, T. Nakanishi, S. Tomura, O. Matsuda, K. Ando, M. Shichiri, Y. Hirata, and F. Marumo. 1989. Plasma endothelin levels in patients with acute renal failure. N. Engl. J. Med. 321:1127.
56. Stewart, D.J., P. Cernacek, K.B. Costello, and J.L. Rouleau. 1992. Elevated cndothelin-1 in heart failure and loss of normal response to postural change. Circulation. 85:510-517.
57. Clozel, M., V. Breu, K. Burri, J.M. Cassai, W. Fischli, G.A. Gray, G. Hirth, B.-M. Löffler, M. Müller, W. Neidhart, and H. Ramuz. 1993. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature (Lond.). 365:759-761.
58. Winn, M., T.W. Vongeldern, T.J. Opgenorth, H.S. Jae, A.S. Tasker, S.A. Boyd, J.A. Kester, R.A. Mantei, R. Bal, B.K. Sorensen, et al. 1996. 2,4-Diarylpyrrolidine-3-carboxylic acids potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722. J. Med. Chem. 39:1039-1048.
59. Yanagisawa, M. 1994. The endothelin system: a new target for therapeutic intervention. Circulation. 89:1320-1322.
60. Allcock, G.H., T.D. Warner, and J.R. Vane. 1995. Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists. Br. J. Pharmacol. 116:2482-2486.
61. Fukuroda, T., T. Fujikawa, S. Ozaki, K. Ishikawa, M. Yano, and M. Nishikibe. 1994. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem. Biophys. Res. Commun. 199:1461-1465.
62. de Nucci, G., R. Thomas, P. D'Orleans-Juste, E. Antunes, C. Walder, T.D. Warner, and J.R. Vane. 1988. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. USA. 85: 9797-9800.
63. Koseki, C., M. Imai, Y. Hirata, M. Yanagisawa, and T. Masaki. 1989. Autoradiographic distribution in rat tissues of binding sites for endothelin: a neuropeptide? Am. J. Physiol. 256:R858-R866.
64. Kuwaki, T., W.H. Cao, Y. Kurihara, H. Kurihara, G.Y. Ling, M. Onodera, K.H. Ju, Y. Yazaki, and M. Kumada. 1996. Impaired ventilatory responses to hypoxia and hypercapnia in mutant mice deficient in endothelin-1. Am. J. Physiol. 270:R1279-R1286.